CytoDyn Leadership Team Set To Attend ESMO Breast Cancer Meeting In Munich, Germany

CytoDyn Inc., a biotechnology company focused on the development of leronlimab, a CCR5 antagonist with potential applications across multiple therapeutic areas, has announced that it will be presenting a poster at the upcoming European Society for Medical Oncology (ESMO) Breast Cancer meeting. The conference is scheduled to take place from May 14 to May 17, 2025, in Munich, Germany. CytoDyn’s poster presentation will occur on May 15, 2025.

The presentation will focus on encouraging survival data observed in patients with metastatic triple-negative breast cancer (mTNBC) who were treated with leronlimab during CytoDyn’s previous oncology clinical trials. In February 2025, the company reported that a review of these trials showed survival rates at 12, 24, and 36 months that favorably compare to those associated with currently approved treatments for this aggressive form of breast cancer.

In a recent update, the company confirmed long-term survival outcomes in a group of patients with mTNBC who had previously received four lines of therapy before being treated with leronlimab. This group includes five patients who have survived more than 48 months following treatment. Among them, four individuals are currently classified as having no evidence of ongoing disease, while the fifth patient is alive with stable disease. CytoDyn has initiated a follow-up protocol to continue monitoring these patients over time.

Dr. Lalezari, said in a statement, “We look forward to sharing details on the progress we have made advancing our clinical development pipeline for leronlimab in oncology. We are also excited to share information about the apparent mechanism of action in long-term surviving patients that we see as a potentially paradigm-shifting development in solid tumor oncology.”

At the ESMO Breast Cancer meeting, Dr. Jay Lalezari will be joined by Dr. Richard Pestell, MD, PhD, AO, Lead Consultant in Preclinical and Clinical Oncology for CytoDyn. Dr. Pestell will present the poster during the designated display session on Thursday, May 15, from 12:00 to 12:45 PM CEST in Hall B0. Several key opinion leaders affiliated with CytoDyn will also be present at the conference to engage with the oncology community and discuss the potential of leronlimab in breast cancer treatment.